山河药辅(300452) - 2024 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2024 reached ¥194,428,356.94, an increase of 3.74% year-over-year, while year-to-date revenue was ¥644,353,357.35, up 0.62% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2024 was ¥26,892,835.36, a decrease of 23.60% year-over-year, with year-to-date net profit at ¥122,425,859.03, down 0.89%[3] - The basic earnings per share for Q3 2024 was ¥0.12, a decline of 20.00% year-over-year, while diluted earnings per share was ¥0.11, down 26.67%[3] - Total operating revenue for Q3 2024 reached ¥644,353,357.35, a slight increase of 0.16% compared to ¥640,355,017.44 in Q3 2023[17] - Net profit for Q3 2024 was ¥123,438,912.72, a decrease of 1.78% from ¥125,689,496.75 in Q3 2023[18] - The net profit attributable to the parent company for Q3 2024 was ¥122,425,859.03, a slight decrease from ¥123,531,091.50 in the same period last year[19] - The total comprehensive income attributable to the parent company was ¥122,425,859.03, compared to ¥123,531,091.50 in the previous year[19] - The company reported earnings per share (EPS) of ¥0.53, unchanged from the previous year[19] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥1,556,908,016.67, reflecting a 0.92% increase from the end of the previous year[3] - Total liabilities decreased to ¥578,721,974.40 from ¥607,461,116.85, a reduction of 4.75%[16] - The company's total assets increased to ¥1,556,908,016.67 from ¥1,542,710,563.50, reflecting a growth of 0.92%[16] - The retained earnings rose to ¥505,949,215.15 from ¥441,677,120.87, an increase of 14.58%[16] Cash Flow - The company's cash flow from operating activities for the year-to-date period was ¥24,692,775.67, a significant decrease of 47.71% compared to the previous year[3] - Operating cash inflow for the period was ¥558,384,420.67, slightly up from ¥552,910,610.23 year-on-year[21] - The net cash flow from operating activities was ¥24,692,775.67, down from ¥47,218,824.42 in the previous year[21] - Cash flow from investment activities showed a net inflow of ¥15,747,073.80, a significant improvement from a net outflow of ¥317,186,893.30 last year[21] - The net cash flow from financing activities was -¥75,593,169.05, compared to a positive inflow of ¥236,941,575.27 in the same period last year[22] - The cash and cash equivalents at the end of the period stood at ¥115,678,368.72, up from ¥89,701,241.43 at the end of the previous year[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,713[9] - The largest shareholder, Yin Zhenglong, holds 26.90% of shares, totaling 63,057,454 shares[9] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 10.25% of shares, totaling 24,042,359 shares[9] - Liu Tao and Liu Jia hold 1.67% and 1.62% of shares, totaling 3,921,033 and 3,787,043 shares respectively[9] - The company repurchased 1,825,500 shares by the end of Q3 2024[11] - The total number of restricted shares at the beginning of the period was 47,660,415, with 22,620 shares released during the period[13] - The total number of restricted shares at the end of the period is 47,647,320[13] - The company has no changes in the top 10 shareholders due to margin trading activities[11] - The report indicates that there are no significant changes in the shareholding structure among the top shareholders[11] - The company has not disclosed any related party transactions among the top shareholders[11] Operational Metrics - Accounts receivable increased by 60.87% to ¥131,740,000, primarily due to increased sales[6] - Prepayments rose by 296.41% to ¥29,984,400, mainly due to increased advance payments for raw materials[6] - Short-term borrowings increased by 103.17% to ¥20,338,700, attributed to new bank loans during the reporting period[6] - The company reported a 581.85% increase in financial expenses to ¥8,844,000, mainly due to increased interest expenses on convertible bonds[8] - Cash and cash equivalents decreased to ¥138,597,190.08 from ¥173,962,875.93 at the beginning of the period, a decline of 20.31%[16] - Accounts receivable increased significantly to ¥131,743,991.23 from ¥81,892,875.33, representing a growth of 60.83%[16] - Inventory levels rose to ¥98,777,247.13, compared to ¥94,103,555.20 at the start of the period, an increase of 5.06%[16] - Short-term borrowings increased to ¥20,338,711.12 from ¥10,010,663.89, marking a rise of 103.29%[16] - Total operating costs amounted to ¥526,758,558.87, up from ¥515,538,731.29 in the previous year, reflecting an increase of 2.36%[18] - The company received cash from sales of goods and services amounting to ¥549,398,385.38, an increase from ¥517,377,590.61 in the previous year[20] - The company paid ¥371,176,213.40 for goods and services, compared to ¥369,079,693.62 in the same period last year[21]